A trial of LY4045004
Latest Information Update: 07 Nov 2024
Price :
$35 *
At a glance
- Drugs LY 4045004 (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 07 Nov 2024 New trial record
- 01 Nov 2024 According to an Eli Lilly and Company media release, expected to enter the clinic in the first half of 2025.